Last reviewed · How we verify
NCT03941171
Is Periacetabular Osteotomy Superior to Progressive Resistance Training?
NA trial testing PAO in Hip Dysplasia in 69 participants. Completed in 15 September 2025.
15 September 2025
Quick facts
| Lead sponsor | University of Aarhus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 1 July 2019 |
| Primary completion | 15 September 2025 |
| Estimated completion | 15 September 2025 |
| Sites | 3 locations across Denmark, Norway |
Drugs / interventions tested
- PAO
- Usual care after PAO
- PRT
Conditions studied
- Hip Dysplasia — all drugs for Hip Dysplasia →
Sponsor
University of Aarhus
Who can join
Adults 18 to 40, any sex, with Hip Dysplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this study is to examine if Periacetabular Osteotomy (PAO) followed by 4 months of usual care followed by 8 months of progressive resistance training (PRT) is superior to 12 months of a PRT intervention in patients with hip dysplasia eligible for PAO in terms of self-reported pain on the HAGOS questionnaire. Secondary aims are to investigate changes in patient-reported symptoms, physical function in daily living, physical function in sport and recreation, hip and/or groin-related quality of life, generic health status, functional performance, muscle strength, physical activity and adverse events between PAO followed by usual care+PRT compared to PRT only. We hypothesise that in patients with hip dysplasia, PAO followed by usual care+PRT, results in significantly less pain at 12 months follow-up, compared to PRT only.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of periacetabular osteotomy followed by progressive resistance training compared to progressive resistance training as non-surgical treatment in patients with hip dysplasia (PreserveHip) - a protocol for a randomised controlled trial.
Reimer LCU, Jakobsen SS, Jakobsen SS, Mortensen L, et al · · 2019 · cited 5× · PMID 31874882 · DOI 10.1136/bmjopen-2019-032782
Verify or expand the search:
- PubMed search for NCT03941171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hip Dysplasia
Currently open trials in the same condition.
- NCT07023094 — PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery · Phase 4 · recruiting
- NCT06891196 — Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment · active not recruiting
- NCT06189781 — Pain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy · Phase 4 · recruiting
- NCT05366712 — Nexus Evaluation Primary Trident II Uncemented Shell · NA · active not recruiting
- NCT04943328 — Cemented TrendHip® - Multicenter PMCF Study on Total Indications · NA · active not recruiting
Other University of Aarhus trials
Trials by the same sponsor.
- NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
- NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
- NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
- NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03941171 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
- Last refreshed: 18 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing